Aptose Biosciences (NASDAQ:APTO) Stock Rating Reaffirmed by HC Wainwright

Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $7.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Aptose Biosciences’ Q2 2024 earnings at ($0.58) EPS, Q3 2024 earnings at ($0.64) EPS, Q4 2024 earnings at ($0.69) EPS and FY2024 earnings at ($2.62) EPS.

APTO has been the subject of a number of other reports. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price target on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. StockNews.com initiated coverage on Aptose Biosciences in a research note on Friday. They set a “hold” rating for the company. Finally, Canaccord Genuity Group decreased their price target on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.83.

View Our Latest Analysis on APTO

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.89 on Friday. Aptose Biosciences has a 12-month low of $0.85 and a 12-month high of $6.00. The firm has a market capitalization of $16.10 million, a price-to-earnings ratio of -0.14 and a beta of 1.39. The business has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.73.

Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. On average, equities analysts anticipate that Aptose Biosciences will post -2.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTOFree Report) (TSE:APS) by 40.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,666 shares of the biotechnology company’s stock after purchasing an additional 21,334 shares during the period. Annandale Capital LLC owned approximately 0.99% of Aptose Biosciences worth $209,000 as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.